Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on March 31, 2025
BOS Reports Financial Results for the Fourth Quarter and Full Year 2024
GlobeNewswire
·
March 31, 2025
Net Income Rises 14.7% Year-Over-Year on Increased Gross Margin, Efficient Operations Provides Initial 2025 Outlook for Further 10% Growth in Sales and Net Income RISHON LE ZION, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- BOS Better Online Solutions Ltd. …
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
GlobeNewswire
·
March 31, 2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high …
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
GlobeNewswire
·
March 31, 2025
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences …
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 31, 2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 …
BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)
GlobeNewswire
·
March 31, 2025
BX211 was safe and well-tolerated BX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than …
Azimut to Initiate a Scoping Study on the Patwon Gold Zone at its Flagship Elmer Project
GlobeNewswire
·
March 31, 2025
Prospecting Continues to Deliver Excellent Gold and Copper Results Up to 181.5 g/t Au, 345 g/t Ag, 301 g/t Te (Gabbro Zone) Up to 9.62 g/t Au, 8.43 g/t Ag, 13.4 g/t Te (Gabbro East) …
Azimut lance une étude d’orientation pour la Zone aurifère Patwon sur son projet-phare Elmer
GlobeNewswire
·
March 31, 2025
La prospection continue de livrer d’excellents résultats en or et en cuivre Jusqu’à 181,5 g/t Au, 345 g/t Ag, 301 g/t Te (Zone Gabbro) Jusqu’à 9,62 g/t Au, 8,43 g/t Ag, 13,4 g/t Te (Gabbro Est) Jusqu’à 5,09 g/t Au, 172 g/t Ag, 7,53 % Cu, 670 g/t Bi (Wolf …
First Atlantic Nickel Announces $1M Premium No Warrant Charity Flow Through Private Placement
GlobeNewswire
·
March 31, 2025
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) announces that it intends to complete a non-brokered private placement financing of up to …
Enlight Announces the Financial Close for Project Country Acres
GlobeNewswire
·
March 31, 2025
The debt financing package includes $773 million of construction loans Country Acres consists of 403 MW of solar generation and 688 MWh of energy storage capacity, and is expected to reach full COD during the second half of 2026 TEL AVIV, Israel, March 31, …
Ero Copper Extends Precious Metals Purchase Arrangements with Royal Gold by US$50 million at the Xavantina Operations
GlobeNewswire
·
March 31, 2025
(all amounts in US dollars, unless otherwise noted) VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) ("Ero" or the “Company”) is pleased to announce that, in return for upfront proceeds of $50 million, …
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
GlobeNewswire
·
March 31, 2025
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics Clinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy (“DMD …